Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Efficacy of All-Trans-Retinoic Acid in High-Risk Acute Myeloid Leukemia with Overexpression of EVI1

Efficacy of All-Trans-Retinoic Acid in High-Risk Acute Myeloid Leukemia with Overexpression of EVI1 Oncol Ther (2019) 7:121–130 https://doi.org/10.1007/s40487-019-0095-9 ORIGINAL RESEARCH Efficacy of All-Trans-Retinoic Acid in High-Risk Acute Myeloid Leukemia with Overexpression of EVI1 . . . . Etienne Paubelle Adriana Plesa Sandrine Hayette Mohamed Elhamri . . . Florence Zylbersztejn Olivier Hermine Gilles Salles Xavier Thomas Received: January 9, 2019 / Published online: May 22, 2019 The Author(s) 2019 addition of ATRA might be of benefit in the ABSTRACT treatment of patients with EVI1-positive AML. Introduction: EVI1 (MECOM)-positive acute Keywords: Acute myeloid leukemia; All-trans- myeloid leukemia (AML) cells have shown retinoic acid; EVI1; Leukemia stem cells; in vitro sensitivity to all-trans-retinoic acid MECOM (ATRA) by inducing differentiation, cell death, and decreased leukemic engraftment. Methods: In this pilot study, we investigated INTRODUCTION the response to ATRA in 13 high-risk AML patients with overexpression of EVI1. Acute myeloid leukemia (AML) is the predomi- Results: Seven of the 13 patients (53.8%) nant acute leukemia among adults, character- achieved complete remission (CR), and ized by an accumulation of malignant response can be combined with a decreased of immature myeloid precursors. It represents a the leukemia stem cell pool. heterogeneous group of diseases with different Conclusion: These primary results tend to responses to treatment, which can be http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Efficacy of All-Trans-Retinoic Acid in High-Risk Acute Myeloid Leukemia with Overexpression of EVI1

Download PDF
10 pages

Loading next page...
 
/lp/springer-journals/efficacy-of-all-trans-retinoic-acid-in-high-risk-acute-myeloid-z34YQpEz3n
Publisher
Springer Journals
Copyright
Copyright © 2019 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-019-0095-9
Publisher site
See Article on Publisher Site

Abstract

Oncol Ther (2019) 7:121–130 https://doi.org/10.1007/s40487-019-0095-9 ORIGINAL RESEARCH Efficacy of All-Trans-Retinoic Acid in High-Risk Acute Myeloid Leukemia with Overexpression of EVI1 . . . . Etienne Paubelle Adriana Plesa Sandrine Hayette Mohamed Elhamri . . . Florence Zylbersztejn Olivier Hermine Gilles Salles Xavier Thomas Received: January 9, 2019 / Published online: May 22, 2019 The Author(s) 2019 addition of ATRA might be of benefit in the ABSTRACT treatment of patients with EVI1-positive AML. Introduction: EVI1 (MECOM)-positive acute Keywords: Acute myeloid leukemia; All-trans- myeloid leukemia (AML) cells have shown retinoic acid; EVI1; Leukemia stem cells; in vitro sensitivity to all-trans-retinoic acid MECOM (ATRA) by inducing differentiation, cell death, and decreased leukemic engraftment. Methods: In this pilot study, we investigated INTRODUCTION the response to ATRA in 13 high-risk AML patients with overexpression of EVI1. Acute myeloid leukemia (AML) is the predomi- Results: Seven of the 13 patients (53.8%) nant acute leukemia among adults, character- achieved complete remission (CR), and ized by an accumulation of malignant response can be combined with a decreased of immature myeloid precursors. It represents a the leukemia stem cell pool. heterogeneous group of diseases with different Conclusion: These primary results tend to responses to treatment, which can be

Journal

Oncology and Therapy – Springer Journals

Published: May 22, 2019

References

  • Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
    Döhner, H; Estey, E; Grimwade, D
  • Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia
    Lugthart, S; Groschel, S; Beverloo, HB
  • Aberrant EVI1 expression in acute myeloid leukaemia
    Hinai, AA; Valk, PJ
  • High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities
    Groschel, S; Lugthart, S; Schlenk, RF
  • High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients
    Barjesteh, WDKS; Erpelinck, C; Putten, WL
  • Predictive value of high EVI1 expression in AML patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation in first CR
    He, X; Wang, Q; Cen, J
  • Point mutations in two EVI1 Zn fingers abolish EVI1-GATA1 interaction and allow erythroid differentiation of murine bone marrow cells
    Laricchia-Rabbio, L; Fazzina, R; Li, D
  • The oncogene EVI1 enhances transcriptional and biological responses of human myeloid cells to all-trans retinoic acid
    Steinmetz, B; Hackl, H; Slabakova, E
  • Expression of the Zn finger gene, EVI-1, in acute promyelocytic leukemia
    Xi, ZF; Russell, M; Woodward, S
  • All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results
    Castaigne, S; Chomienne, C; Daniel, MT
  • Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies
    Ablain, J; Leiva, M; Peres, L; Fonsart, J; Anthony, E; The, H
  • All-trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase II randomized trial
    Belhabri, A; Thomas, X; Wattel, E
  • Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial
    Milligan, DW; Wheatley, K; Littlewood, T
  • A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment
    Burnett, AK; Milligan, D; Prentice, AG
  • Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial
    Burnett, AK; Hills, RK; Milligan, DW
  • Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin ± all-trans retinoic acid ± granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome
    Estey, EH; Thall, PF; Pierce, S
  • Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia
    Schlenk, RF; Frohling, S; Hartmann, F
  • All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study
    Schlenk, RF; Lübbert, M; Benner, A
  • Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells
    Martelli, MP; Gionfriddo, I; Mezzasoma, F
  • Arsenic trioxide and all-trans-retinoic acid selectively exert synergistic cytotoxicity against FLT3-ITD AML cells via co-inhibition of FLT3 signaling pathways
    Wang, LN; Tang, YL; Zhang, YC
  • All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD + leukemia stem cells in vitro and in vivo
    Ma, HS; Greenblatt, SM; Shirley, CM
  • Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia
    Boutzen, H; Saland, E; Larrue, C
  • Primary acute myeloid leukemia cells with overexpression of EVI-1 are sensitive to all-trans retinoic acid
    Verhagen, HJMP; Smit, MA; Rutten, A
  • High frequency of CD34+CD38−/low immature leukemia cells is correlated with unfavorable prognosis in acute myeloid leukemia
    Plesa, A; Dumontet, C; Mattei, E
  • Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells
    Goyama, S; Yamamoto, G; Shimabe, M
  • Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia
    Gentles, AJ; Plevritis, SK; Majeti, R; Alizadeh, AA
  • Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation
    Nasr, R; Guillemin, MC; Ferhi, O
  • Retinoic acid and arsenic trioxide for acute promyelocytic leukemia
    Lo-Coco, F; Avvisati, G; Vignetti, M
  • Retinoic acid-induced CD38 expression in HL-60 myeloblastic leukemia cells regulates cell differentiation or viability depending on expression levels
    Lamkin, TJ; Chin, V; Varvayanis, S
  • The bromodomain inhibitor JQ1 enhances the responses to all-trans retinoic acid in HL-60 and MV4-11 leukemia cells
    Kang, C; Kim, CY; Kim, HS; Park, SP; Chung, HM
  • Targeting the SUMO pathway primes all-trans retinoic acid-induced differentiation of non promyelocytic acute myeloid leukemias
    Baik, H; Boulanger, M; Hosseini, M
  • Anti-leukemic effects of all-trans retinoic acid in combination with daratumumab in acute myeloid leukemia
    Buteyn, NJ; Fatehchand, K; Santhanam, R
  • Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia
    Schenk, T; Chen, WC; Göllner, S
  • Reprogramming acute myeloid leukemia into sensitivity for retinoic-acid-driven differentiation
    Gils, N; Verhagen, HJMP; Smit, L
  • Aberrant promoter methylation of the retinoic acid receptor alpha gene in acute promyelocytic leukemia
    Chim, CS; Wong, SY; Pang, A
  • Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1
    Lugthart, S; Figueroa, ME; Bindels, E
  • Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia
    Vazquez, I; Maicas, M; Cervera, J